ES2118399T3 - Nuevos glucocorticoides. - Google Patents

Nuevos glucocorticoides.

Info

Publication number
ES2118399T3
ES2118399T3 ES94912531T ES94912531T ES2118399T3 ES 2118399 T3 ES2118399 T3 ES 2118399T3 ES 94912531 T ES94912531 T ES 94912531T ES 94912531 T ES94912531 T ES 94912531T ES 2118399 T3 ES2118399 T3 ES 2118399T3
Authority
ES
Spain
Prior art keywords
pct
groups
radical
date oct
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94912531T
Other languages
English (en)
Inventor
Hans Joachim Zentel
Michael Topert
Henry Laurent
Thomas Brumby
Peter Esperling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Application granted granted Critical
Publication of ES2118399T3 publication Critical patent/ES2118399T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCRIBEN NUEVOS GLUCOCORTICOIDES DE LA FORMULA GENERAL (I): R - VAL - O - GC DONDE O - GC ES EL RESTO DE UN 21 - HIDROXI CORTICOIDE ACTIVO ANTIINFLAMATORIO, VAL REPRESENTA UNA DE LAS 21 POSICIONES DEL RESTO VALINA QUE SE ENCUENTRA EN EL CORTICOIDE Y R ES UN ATOMO DE HIDROGENO O UN RESIDUO HIDROCARBURO TENIENDO HASTA 32 ATOMOS DE CARBONO Y SI SE REQUIERE SUSTITUIDO POR GRUPOS HIDROXI, GRUPOS AMINO, GRUPOS OXO Y/O ATOMOS DE HALOGENO Y/O INTERRUMPIDO POR ATOMOS DE OXIGENO, GRUPOS SO{SUB,2} Y/O GRUPOS NH. SE DESCRIBEN TAMBIEN LAS SALES DE LOS INDICADOS CORTICOIDES.
ES94912531T 1993-04-07 1994-03-24 Nuevos glucocorticoides. Expired - Lifetime ES2118399T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4311987A DE4311987A1 (de) 1993-04-07 1993-04-07 Neue Glucocorticoide

Publications (1)

Publication Number Publication Date
ES2118399T3 true ES2118399T3 (es) 1998-09-16

Family

ID=6485335

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94912531T Expired - Lifetime ES2118399T3 (es) 1993-04-07 1994-03-24 Nuevos glucocorticoides.

Country Status (10)

Country Link
US (1) US5616573A (es)
EP (1) EP0693080B1 (es)
JP (1) JPH08508727A (es)
AT (1) ATE165366T1 (es)
AU (1) AU696090B2 (es)
CA (1) CA2158643A1 (es)
DE (2) DE4311987A1 (es)
DK (1) DK0693080T3 (es)
ES (1) ES2118399T3 (es)
WO (1) WO1994022898A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2167818A1 (en) 1993-08-02 1995-02-09 Robert George Whittaker Therapeutic compound - fatty acid conjugates
US5952499A (en) * 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
ES3046537T3 (en) 2016-11-08 2025-12-02 Regeneron Pharma Steroids and protein-conjugates thereof
EP3600333A4 (en) 2017-03-21 2020-11-25 The Scripps Research Institute CU AND NI-CATALYZED DECARBOXYLATIVE BORYLATION REACTIONS
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
SG11202006510XA (en) * 2018-01-08 2020-08-28 Regeneron Pharma Steroids and antibody-conjugates thereof
CN118955710A (zh) 2018-05-09 2024-11-15 里珍纳龙药品有限公司 抗msr1抗体及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US4997814A (en) * 1988-06-09 1991-03-05 Allelix Biopharmaceuticals, Inc. Pharmaceutical compositions and use thereof in treating inflammation
JPH04273892A (ja) * 1991-02-27 1992-09-30 Kao Corp 新規な21−置換ステロイド化合物
EP1236470A3 (en) * 1991-11-22 2004-09-01 Alcon Laboratories, Inc. Angiostatic steroids
US5536727A (en) * 1992-05-20 1996-07-16 Merck & Co., Inc. 17-Ethers and thioethers of 4-aza-steroids
JPH07508039A (ja) * 1992-05-20 1995-09-07 メルク エンド カンパニー インコーポレーテッド 4−アザステロイドのエステル誘導体

Also Published As

Publication number Publication date
US5616573A (en) 1997-04-01
AU696090B2 (en) 1998-09-03
EP0693080B1 (de) 1998-04-22
WO1994022898A1 (de) 1994-10-13
JPH08508727A (ja) 1996-09-17
ATE165366T1 (de) 1998-05-15
CA2158643A1 (en) 1994-10-13
AU6504894A (en) 1994-10-24
DK0693080T3 (da) 1999-02-22
DE4311987A1 (de) 1994-10-13
DE59405797D1 (de) 1998-05-28
EP0693080A1 (de) 1996-01-24

Similar Documents

Publication Publication Date Title
DK0740674T3 (da) Polyurethanharpikser, fremgangsmåde til fremstilling deraf, samt anvendelse deraf i vandfortyndelige overtræksmidler
DE69328550D1 (de) Verwendung von fulleren-derivaten in diagnostischen und/oder therapeutischen mitteln
ES2118399T3 (es) Nuevos glucocorticoides.
ATE342927T1 (de) Nicht-elastomere polyurethanzusammensetzungen
DE69637890D1 (de) Monoklonaler antikörper für die inhibierung von hiv-1-hüllgykoprotein-vermittelte membranfusion
IT1271325B (it) Composti diastereomericamente puri derivati da 3-oxo e 3-tioxo-4-azaandrostani e loro uso come antiandrogeni
TW248566B (es)
DK455088D0 (da) Syntetiske receptoranaloger
ES2062805T3 (es) Procedimiento para la preparacion de sulfatos ciclicos.
ATE166342T1 (de) Desferrioxamine-b salze und ihre verwendung als oral wirksame eisen- chelatbildner
DE69433238D1 (de) Pflanzenpromoter, microorganismen und pflanzenzellen mit einer expressionseinheit für ein gewünschtes protein, das besagten promoter enthält
ES2100060T3 (es) Aminooxi-compuestos ciclicos inhibidores de ornitina descarboxilasa.
DE59408087D1 (de) Substituierte heteroarylalkylthiopyridine zur bekämpfung von helicobacter bakterien
ATE200624T1 (de) Verwendung von 4'-iodo - 4 - deoxydoxorubicin zur behandlung von amyloidosis
NO980376L (no) Rengjörende blanding omfattende en alifatisk hydrokarbonforbindelse med minst to aromatiske substituenter
ATE209647T1 (de) Pyridiniumsalze und ihre verwendung zur bekämpfung von helicobacter-bakterien
FI962301A0 (fi) Substituoidut aminoalkyyliaminopyridiinit
ES8606272A1 (es) Procedimiento para preparar derivados carboxialquildipepti- dicos
DE69313842D1 (de) Teilweise modifizierte und retro-invertierte tetrapeptides analogue von fragmenten des c reaktiven proteins
ATE150009T1 (de) Verzweigte aminooxy-amino-alkan-derivate als ornithin-decarboxylase inhibitoren
ATE108420T1 (de) Verfahren zur konditionierung von abfallschwefelsäure.
CZ145095A3 (en) Novel triazoloquinazolines, process of their preparation and use
ATE173737T1 (de) 3-(aminoacyl-amino)-saccharide und verfahren zu ihrer herstellung
ATE167191T1 (de) Verfahren zur stereoselektiven reduktion von 17- oxo-steroiden
KR920701126A (ko) N-보호된 디알킬(2s,3s)-3-에틸아스팔테이트의 제조방법

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 693080

Country of ref document: ES